Literature DB >> 24037208

The antimicrobial susceptibility, biofilm formation and genotypic profiles of Staphylococcus haemolyticus from bloodstream infections.

Patricia Vollú Silva1, Raquel Souza Cruz, Luiz Sérgio Keim, Geraldo Renato de Paula, Bernadete Teixeira Ferreira Carvalho, Leonardo Rocchetto Coelho, Maria Cícera da Silva Carvalho, Joel Mauricio Corrêa da Rosa, Agnes Marie Sá Figueiredo, Lenise Arneiro Teixeira.   

Abstract

We analysed the antimicrobial susceptibility, biofilm formation and genotypic profiles of 27 isolates of Staphylococcus haemolyticus obtained from the blood of 19 patients admitted to a hospital in Rio de Janeiro, Brazil. Our analysis revealed a clinical significance of 36.8% and a multi-resistance rate of 92.6% among these isolates. All but one isolate carried the mecA gene. The staphylococcal cassette chromosome mec type I was the most prevalent mec element detected (67%). Nevertheless, the isolates showed clonal diversity based on pulsed-field gel electrophoresis analysis. The ability to form biofilms was detected in 66% of the isolates studied. Surprisingly, no icaAD genes were found among the biofilm-producing isolates.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24037208      PMCID: PMC3970699          DOI: 10.1590/0074-0276108062013022

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


Staphylococcus haemolyticus isolates are saprophytic bacteria with the ability to colonise human skin and mucosal membranes. However, these coagulase-negative bacteria have recently emerged as hospital-associated pathogens, mainly in immune-compromised patients. Recent studies have identified S. haemolyticus as an important cause of primary bloodstream infections associated with the use of central venous catheters (CVC) (Keim et al. 2011, Barros et al. 2012, Bouchami et al. 2012). Notably, S. haemolyticus isolates exhibit high resistance profiles and quite frequently display reduced susceptibility to glycopeptide antibiotics (Ahlstrand et al. 2011, Barros et al. 2012). The bacterial ability to form biofilms is thought to be an important mechanism involved in CVC-related infections and in other device-associated diseases. Biofilm formation among staphylococci is mediated by the ica operon, which encodes the enzymes involved in the synthesis of poly-N-acetylglucosamine/polysaccharide intercellular adhesin (PNAG/PIA). Nevertheless, PNAG/PIA-independent biofilm matrices have been described in these cocci, including Staphylococcus epidermidis (Araujo et al. 2006). However, the biofilms formed by S. haemolyticus have not yet been subjected to more detailed studies. In this paper, 27 consecutive isolates initially identified as methicillin-resistant S. haemolyticus (MRSHa) using the Vitek Automatic System with GPS-105 {BioMérieux Brasil, Rio de Janeiro (RJ), Brazil} were studied. These isolates were obtained from blood samples collected from 17 adult and two paediatric patients who were admitted in different clinical settings to a tertiary hospital in RJ from 2007-2008. Because different isolates recovered from the blood of an individual patient can display different genetic profiles, more than one isolate per patient was included in this study. The exclusion criterion was the presence of isolates from the same patient displaying an identical pulsed-field electrophoresis pattern. In such cases, only one of the repeat isolates was included. The identification of the isolates was confirmed via polymerase chain reaction (PCR) amplification of the mvaA gene, as described previously (Barros et al. 2012). S. haemolyticus isolates were considered clinically significant based on the criteria described by the Centers for Diseases Control and Prevention (CDC), which includes: (i) a patient with a recognised pathogen cultured from two or more blood cultures collected within a period of two days, (ii) risk factors for bloodstream infection, (iii) classical clinical manifestations and (iv) associated clinical laboratory findings (Horan et al. 2008). Antibiogram tests were carried out as recommended by the Clinical and Laboratory Standards Institute (CLSI 2011). The minimum inhibitory concentration (MIC) was determined for vancomycin and teicoplanin (TEI) (CLSI 2011). Multi-resistance was defined as resistance to three or more classes of antimicrobials, including β-lactams. High-level multi-resistance was defined as an isolate displaying resistance to six or more drugs. PCR was used to detect mecA (Araujo et al. 2006), encoding methicillin resistance and to determine the type of staphylococcal cassette chromosome mec (SCCmec) (Boye et al. 2007, Berglund et al. 2008, Zhang et al. 2009). PCR analysis was also employed to assess the ica operon (Araujo et al. 2006). The icaAD primers exhibited 100% correspondence to the ica sequence of S. haemolyticus (GenBank accession FJ472951.2). Additionally, a PCR probe amplified with specific icaAD primers (Araujo et al. 2006) was labelled using the DIG High Prime DNA Labelling and Detection Starter Kit II (Roche Diagnostics, Mannhein, Germany) and was used for dot-blot hybridisation experiments with chromosomal DNA to confirm the PCR-negative results for icaAD genes. The ica-positive S. epidermidis isolate 70D (Araujo et al. 2006) was used as a positive control for the assessment of ica via PCR or dot-blot-hybridisation and as a negative control for the experiment involving proteinase K. Biofilm formation was investigated using a microtitre-based system and the biofilm units (BU) was calculated as previously defined (Araujo et al. 2006). The 27 isolates were analysed through pulsed-field gel electrophoresis (PFGE) following chromosomal DNA digestion with the SmaI endonuclease (Teixeira et al. 1995). PFGE types were defined on the basis of DNA-banding patterns according to visual criteria. Isolates exhibiting PFGE patterns that differed from one another by fewer than four bands were assigned a common capital letter, with numerical indices representing subtypes, as described previously (Teixeira et al. 1995). An unpaired Student's t test was used for the majority of statistical analyses, except for the determination of correlations between multi-resistance and biofilms and between high-level resistance among clinically significant and non-significant isolates, for which Fisher's exact probability test was chosen. A level of 0.05 was considered significant for both statistical tests. Based on the CDC criteria, clinically significant S. haemolyticus isolates were collected from seven of the 19 patients studied (36.8%). Among these individuals, patient 7 (P7) presented two isolates with dissimilar genetic profiles. In this case, the clinically significant S. haemolyticus strain could be identified based on the PFGE type of the isolates compared to those excluded from the study due to showing an identical pattern to the significant isolate. In one other patient (P4), the significant isolate could not be identified on the basis of molecular techniques given that the two isolates recovered showed distinct genetic profiles. A total of 13 isolates recovered from eight patients were considered contaminants. Five isolates collected from four patients could not be classified due to a lack of sufficient patient data (Table). Eight isolates were obtained from 19 patients (42.1%) who presented with malignant tumours, three of whom exhibited community infections (15.8%), while the remainder showed vascular cerebral accident, alcoholic liver cirrhosis, severe hypertension, type II diabetes mellitus and acute pulmonary oedema. Age data are reported for 14 patients. The mean age ( ± standard deviation) of adult patients was 50 ± 22 years (range, 24-93 years). Additionally, two patients were classified as paediatric (> 2 years old).
TABLE

Antimicrobial resistance, pulsed-field gel electrophoresis (PFGE) patterns, staphylococcal cassette chromosome mec (SCC mec ) types and biofilm formation of 27 Staphylococcus haemolyticus isolated from blood

Isolate (patient number, sex, age)Collection dateHospital unitAntimicrobial resistancePFGESCC mec Biofilm c
05/08 (P1, M, 41)6 Jan 2008Intensive carePEN, OXA, CEF, CLI, ERY, GEN, CIP, SXT, TEIKVIINP
33/08(P2, F, 37)4 Nov 2007Internal medicinePEN, OXA, CEF, CLI, ERY, TET, GEN, CIP, SXTKVII0.56 ± 0.17
37/08 (P2)4 Nov 2007NeurosurgeryPEN, OXA, CEF, CLI, TET, GEN, CIP, SXTIVII0.27 ± 0.12
27/08 (P3, M, 24)31 Oct 2007NeurosurgeryPEN, OXA, CEF, CLI, ERY, RIF, GEN, CIP, SXTH 2 INP
47/08 (P3)31 Oct 3007NeurosurgeryPEN, OXA, CEF, CLI, ERY, RIF, GEN, CIP, SXTH 1 I1.32 ± 0.54
32/08 (P4, F, 82)29 Oct 2007Internal medicinePEN, OXA, CEF, CLI, ERY, CHL, GEN, CIP, SXTLVIII0.57± 0.09
43/08 (P4)29 Oct 2007Internal medicinePEN, OXA, CEF, CLI, ERY, GEN, CIP, SXTNDI0.89 ± 0.17
34/08 (P5, F, 34) a 25 Oct 2007Internal medicinePEN, OXA, CEF, CLI, ERY, CHL, CIPJVIIINP
56/08 (P6, F, 93) a 25 Oct 2007Internal medicinePEN, OXA, CEF, CLI, ERY, GEN, CIP, SXTGVIINP
65/08 (P7, F, 25) a 4 Feb 2008Intensive carePEN, OXA, CEF, CLI, ERY, CHL, TET, GEN, CIP, SXTAI1.45 ± 0.38
69/08 (P7)4 Feb 2008Intensive carePEN, OXA, CEF, CLI, ERY, CHL, GEN, CIP, SXTFI0.25 ± 0.10
74/08 (P8, M, 57)28 Jan 2008NeurosurgeryPEN, OXA, CEF, CLI, ERY, CHL, GEN, CIP, SXTAI3.38 ± 0.94
136/08 (P8)28 Jan 2008NeurosurgeryPEN, OXA, CEF, CLI, ERY, CHL, GEN, CIP, SXTBI1.60 ± 0.66
85/08 (P9, M, NR) b 4 Jan 2008Intensive carePEN, OXA, CEF, CHLOVIINP
86/08 (P9)4 Jan 2008Intensive carePEN, OXA, CEF, CLI, ERY, CHL, TET, GEN, CIP, SXTAI2.60 ± 0.46
140/08 (P10, F, NR) a 25 Feb 2008Internal medicinePEN, OXA, CEF, CLI, ERY, CHL, TET, RIF, GEN, CIP, SXTGVIINP
142/08 (P11, M, NR)28 Feb 2008CoronaryPEN, OXA, CEF, CLI, ERY, TET, GEN, CIP, SXTC 1 INP
153/08 (P11)28 Feb 2008CoronaryPEN, OXA, CEF, CLI, ERY, GEN, CIP, SXTC 2 I0.19 ± 0.07
161/08 (P11)28 Feb 2008CoronaryPEN, OXA, CEF, CLI, ERY, GEN, CIP, SXTDI0.19 ± 0.1
155/08 (P12, M, 26) a 26 Feb 2008Intensive carePEN, OXA, CEF, CLI, ERY, CHL, TET, RIF, GEN, CIP, SXTC 1 I0.48 ± 0.19
177/08 (P13, F, 59) b 26 Mar 2008TraumaPEN, OXA, CEF, CLI, ERY, CHL, GEN, CIP, SXTDI0.90 ± 0.07
202/08 (P14, F, 14m)1 Apr 2008Paediatric unitPEN, OXA, CEF, ERY, GEN, CIP, SXTC 1 INP
207/08 (P15, M, 56)7 Apr 2008NeurologyPEN, OXA, CEF, CLI, ERY, RIF, GEN, CIP, SXTNDI0.44 ± 0.11
220/08 (P16, F, NB) b 26 Apr 2008Intensive carePEN, OXA, ERYMINP
283/08 (P17, F, NR) a 8 Jul 2008DialysisPEN, OXA, CEF, CLI, ERY, GEN, CIP, SXTEI0.20 ± 0.06
285/08 (P18, M, NR) b 27 Jun 2008SurgeryPEN, OXA, CEF, ERY, CHL, TET, RIF, GEN, CIP, SXTNVII0.38 ± 0.15
286/08 (P19, M, 62)27 Jun 2008Intensive carePEN, OXA, CEF, ERY, CHL, RIF, GEN, CIP, SXTEI0.24 ± 0.09

a : clinically significant isolates (for patient P4 the clinically significant isolate could not be assigned on the basis of the genotype, since the two isolates recovered had different genetic profiles); b : for these patients, clinical significance could not be evaluate due to lack of sufficient data; c : biofilm values were determined using a microtitre-based method; CEF: cefoxitin (30 µg); CHL: chloramphenicol (30 µg); CIP: ciprofloxacin (5 µg); CLI: clindamycin (2 µg); ERY: erythromycin (15 µg); F: female; GEN: gentamicin (10 µg); M: male; NB: newborn; ND: not-done; NP: non-producer; NR: not reported; OXA: oxacillin (1 µg); PEN: penicillin (10 U); RIF: rifampicin (5 µg); SXT: sulphamethoxazole-trimethoprim (1.25 µg/23.75 µg); TEI: teicoplanin (minimal inhibitory concentration ‰¥ 64 µg/mL); TET: tetracycline (30 µg). P4, P5, P6, P7, P10, P12, P17 were patients with significant bacteraemia.

a : clinically significant isolates (for patient P4 the clinically significant isolate could not be assigned on the basis of the genotype, since the two isolates recovered had different genetic profiles); b : for these patients, clinical significance could not be evaluate due to lack of sufficient data; c : biofilm values were determined using a microtitre-based method; CEF: cefoxitin (30 µg); CHL: chloramphenicol (30 µg); CIP: ciprofloxacin (5 µg); CLI: clindamycin (2 µg); ERY: erythromycin (15 µg); F: female; GEN: gentamicin (10 µg); M: male; NB: newborn; ND: not-done; NP: non-producer; NR: not reported; OXA: oxacillin (1 µg); PEN: penicillin (10 U); RIF: rifampicin (5 µg); SXT: sulphamethoxazole-trimethoprim (1.25 µg/23.75 µg); TEI: teicoplanin (minimal inhibitory concentration ‰¥ 64 µg/mL); TET: tetracycline (30 µg). P4, P5, P6, P7, P10, P12, P17 were patients with significant bacteraemia. The gender distribution among the 19 patients tested was close to equal (47% males and 53% females). Despite the limited number of isolates, 85.7% (6/7) of the clinically significant patients were female. In contrast, only 25% (2/8) of the contaminated patients were females (p = 0.04). We were not able to identify any factor to explain the difference between the two gender groups, except that the two oldest patients were females belonging to the group with clinical significance (Table). Due to the small number of studies on S. haemolyticus epidemiology available in the scientific literature, we could not comparatively analyse the gender data. Thus, studies with a greater number of clinically significant cases are required to clarify this issue. The great majority of the tested S. haemolyticus isolates displayed multi-resistant profiles (25/27; 92.6%). Among the studied isolates, only two were resistant to all of the drugs tested, except glycopeptides, and these two were therefore defined as high-level resistant isolates (> 8 antimicrobials). These high-level resistant MRSHa isolates were found in the group of clinically significant isolates. Statistical analysis was conducted to compare the high-level resistance detected between clinically significant and non-significant isolates (Table) and the obtained p value was close to the limit of significance (p = 0.054). It has been suggested that the intensive use of glycopeptides is associated with increasing resistance to this drug, especially among S. haemolyticus isolates (Ahlstrand et al. 2011). In the present study, isolate 05/08 displayed TEI resistance (MIC = 64 µg/mL) and was only susceptible to tetracycline, chloramphenicol and rifampicin (Table). During the preparation of this paper, a study was published demonstrating clonal dissemination of linezolid-resistant S. haemolyticus isolates exhibiting a G2576T mutation in the 23S rrna gene in a hospital in Brazil (de Almeida et al. 2012). Thus, the high levels of multi-resistance observed in this emergent bacterial pathogen, including resistance to new generation antimicrobial drugs, may have serious implications for the therapeutic treatment of the associated infections. It was suggested that the significant number of IS elements distributed within the S. haemolyticus genome may represent hotspots for the acquisition of resistance genes and could promote rearrangement of genomic DNA, which accelerates bacterial diversification (Bouchami et al. 2012). Only 3.7% (1/27) of the S. haemolyticus isolates tested did not carry the mecA gene based on the absence of the expected 164-base pairs (bp) mecA-fragment. However, in DNA obtained from the mecA-negative isolate 220/08, a 415-bp fragment was amplified corresponding to the IS1272 insertion sequence-like element, which is present in some mec islands, including type I, IV and VI (Boye et al. 2007, Berglund et al. 2008, Zhang et al. 2009). Remarkably, isolate 220/08 was resistant to oxacillin (OXA), but was susceptible to cefoxitin in disk tests. In addition, the MIC value recorded for OXA was 1 µg/mL. It is well known that the OXA MIC interpretative criteria can lead to overestimation of resistance for certain coagulase-negative staphylococci other than S. epidermidis isolates, for which the OXA MICs are between 0.5-2 µg/mL (CLSI 2011). SCCmec type I was identified among 67% (18/27) of the tested isolates (Table). This SCCmec type has been described as the most common type found among nosocomial isolates of MRSHa in the south of Brazil (Mombach et al. 2007). The remaining isolates analysed in the present study were distributed among SCCmec type VII (7/27; 26%) and type VIII (2/27; 7%) strains. The prevalence of SCCmec V in MRSHa isolates had been reported in previous studies (Barros et al. 2012, Bouchami et al. 2012). However, Zong et al. (2011) found a variety of SCCmec types among 19 MRSHa isolates recovered from a hospital in China. Despite the prevalence of SCCmec I, we observed that these isolates displayed considerable genetic diversity. The 27 analysed isolates were classified into 15 PFGE types and two subtypes (Table). A similar clonal diversity was reported in Brazil for S. haemolyticus isolates collected from another hospital (Barros et al. 2012). In contrast, Bouchami et al. (2012) investigated 36 MRSHa isolates from Tunisia and found that 77% of the isolates clustered in only four PFGE types. A collection of 72 isolates of S. haemolyticus from Norway could also be grouped into only seven different clusters, the largest of which consisted of 16 isolates obtained from neonates treated in a neonatal intensive care unit at the same hospital (Fredheim et al. 2009). Thus, it is possible that this difference may be because the patients included in the present study came from different hospital units (Table), while those studied by the cited authors (Fredheim et al. 2009, Bouchami et al. 2012) came from a more limited number of hospital settings. Similar to what has been observed previously (Bouchami et al. 2012), we found that MRSHa isolates displaying different PFGE types could carry the same SCCmec type (Table), suggesting that horizontal transfer of SCCmec is a relatively common event among MRHSa strains. Our data showed that 18 of the isolates (67%) were able to form biofilms (mean BU: 0.89 ± 0.86), eight (44%) of which displayed a high ability to accumulate biofilms (BU ≥ 0.89) (Table). Likewise, Fredheim et al. (2009) found that 74% of the S. haemolyticus isolates analysed could produce biofilms. Despite the limited number of isolates tested in this study, 11 contaminants, four clinically significant MRSHa isolates and three other isolates that could not be classified were able to form a biofilm on an inert polystyrene surface (mean BU: 0.91 ± 1.06, 0.76 ± 0.54 and 1.27 ± 1.19) (Table). Student's t test showed that there was no significant difference between these populations (p > 0.5). Indeed, some contaminants (isolates 47/08, 136/08 and 74/08) showed a high capability to accumulate biofilms (Table). Notably, the only four isolates that were comparatively more susceptible to most of the antimicrobials tested (isolates 34/08, 85/08, 202/08 and 220/08) did not produce biofilms in this study and all of the biofilm producers were classified as showing high-level multi-resistance (p < 0.01) (Table). A relationship between multi-resistance and biofilm formation has also been observed by others (Araujo et al. 2006). Phase variation is a well-known common mechanism of biofilm formation for both ica-positive and negative staphylococci. In this study, we observed that some isolates clustering within a same PFGE type could exhibit quite different biofilm values (Table). It is possible that surface proteins involved in the formation of an ica-negative biofilm matrix might have been influenced by switching transcriptional regulators on or off. Amplification of the icaAD genes was not detected in any of the 27 isolates analysed. The absence of the icaAD genes was confirmed through hybridisation experiments. Similar results have recently been reported by Fredheim et al. (2009), who detected the ica operon in only two of 53 biofilm-producing S. haemolyticus isolates. In the present study, the proteinaceous nature of the ica-independent biofilms was indicated by the significant disruption of the mature biofilms generated by the S. haemolyticus isolates following treatment with 6 U/well proteinase K (Figure). Thus, after treatment with proteinase K, the mean biofilm values for 10 representative MRSHa isolates tested (displaying different biofilm phenotypes) decreased from 0.927 ± 0.358 to 0.19 ± 0.077 (p = 0.002). As expected, the ica-dependent biofilm produced by S. epidermidis 70D (BU = 2.283 ± 0.204) was only slightly affected (1.648 ± 0.169; p = 0.0408) by the proteinase K treatment (B in Figure). Similar results have been found by others (Fredheim et al. 2009). As expected, treatment of mature biofilms with the carbohydrate-oxidant sodium metaperiodate (10 mM/well) did not significantly affect pre-formed biofilms (1.146 ± 0.824; p = 0.26). Previous studies have suggested that extracellular DNA is one of the components of the biofilm matrix formed by S. haemolyticus (Fredheim et al. 2009). However, the incorporation of DNase I (28U/well) into the microtitre-based system did not significantly impair biofilm formation among these isolates (0.878 ± 0.405; p = 0.30).

A: biofilms of representative isolates of Staphylococcus haemolyticus (1: untreated; 2: proteinase K; 3: DNase; 4: sodium metaperiodate); B: microtitre based biofilm of representative isolates (1, 2: 33/08; 3, 4: 37/08; 5, 6: 69/08; 7, 8: ica -dependent biofilm producer Staphylococcus epidermidis 70D); even numbers: proteinase K treatment; odd numbers: untreated.

In conclusion, our analyses demonstrated that S. haemolyticus isolates collected from human blood, representing both clinically significant and contaminant isolates, showed clonal diversity, high-level antimicrobial multi-resistance and an ability to form ica-independent, proteinaceous biofilms. The increasing importance of these multi-resistant isolates in hospital infections in different countries confirms the fitness of these bacteria as opportunistic nosocomial pathogens. Additional studies are necessary to clarify the primary molecules involved in the composition and modulation of the ica-independent biofilms formed by S. haemolyticus.
  14 in total

1.  Clonal dissemination of linezolid-resistant Staphylococcus haemolyticus exhibiting the G2576T mutation in the 23S rRNA gene in a tertiary care hospital in Brazil.

Authors:  Lara M de Almeida; Nilton Lincopan; Maria Rita E de Araújo; Elsa M Mamizuka
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

2.  Staphylococcus haemolyticus as an important hospital pathogen and carrier of methicillin resistance genes.

Authors:  E M Barros; H Ceotto; M C F Bastos; K R N Dos Santos; M Giambiagi-Demarval
Journal:  J Clin Microbiol       Date:  2011-10-05       Impact factor: 5.948

3.  A new multiplex PCR for easy screening of methicillin-resistant Staphylococcus aureus SCCmec types I-V.

Authors:  K Boye; M D Bartels; I S Andersen; J A Møller; H Westh
Journal:  Clin Microbiol Infect       Date:  2007-04-02       Impact factor: 8.067

4.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.

Authors:  Teresa C Horan; Mary Andrus; Margaret A Dudeck
Journal:  Am J Infect Control       Date:  2008-06       Impact factor: 2.918

5.  High prevalence of mec complex C and ccrC is independent of SCCmec type V in Staphylococcus haemolyticus.

Authors:  O Bouchami; A Ben Hassen; H de Lencastre; M Miragaia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-08-07       Impact factor: 3.267

6.  Biofilm formation by Staphylococcus haemolyticus.

Authors:  Elizabeth Gladys Aarag Fredheim; Claus Klingenberg; Holger Rohde; Stephanie Frankenberger; Peter Gaustad; Trond Flaegstad; Johanna Ericson Sollid
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

7.  Novel type of staphylococcal cassette chromosome mec in a methicillin-resistant Staphylococcus aureus strain isolated in Sweden.

Authors:  Carolina Berglund; Teruyo Ito; Megumi Ikeda; Xiao Xue Ma; Bo Söderquist; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

8.  Novel staphylococcal cassette chromosome mec type, tentatively designated type VIII, harboring class A mec and type 4 ccr gene complexes in a Canadian epidemic strain of methicillin-resistant Staphylococcus aureus.

Authors:  Kunyan Zhang; Jo-Ann McClure; Sameer Elsayed; John M Conly
Journal:  Antimicrob Agents Chemother       Date:  2008-12-08       Impact factor: 5.191

9.  Geographic spread of epidemic multiresistant Staphylococcus aureus clone in Brazil.

Authors:  L A Teixeira; C A Resende; L R Ormonde; R Rosenbaum; A M Figueiredo; H de Lencastre; A Tomasz
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

10.  Diversity of SCCmec elements in methicillin-resistant coagulase-negative staphylococci clinical isolates.

Authors:  Zhiyong Zong; Chunhong Peng; Xiaoju Lü
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

View more
  11 in total

Review 1.  Clinical Infections, Antibiotic Resistance, and Pathogenesis of Staphylococcus haemolyticus.

Authors:  Hala O Eltwisy; Howida Omar Twisy; Mahmoud Hr Hafez; Ibrahim M Sayed; Mohamed A El-Mokhtar
Journal:  Microorganisms       Date:  2022-05-31

2.  Comparison of the etiological relevance of Staphylococcus haemolyticus and Staphylococcus hominis.

Authors:  Hagen Frickmann; Andreas Hahn; Romy Skusa; Nils Mund; Vivian Viehweger; Thomas Köller; Kerstin Köller; Norbert Georg Schwarz; Karsten Becker; Philipp Warnke; Andreas Podbielski
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-19       Impact factor: 3.267

Review 3.  The Staphylococcal Biofilm: Adhesins, Regulation, and Host Response.

Authors:  Alexandra E Paharik; Alexander R Horswill
Journal:  Microbiol Spectr       Date:  2016-04

4.  Impact of Insertion Sequences and Recombination on the Population Structure of Staphylococcus haemolyticus.

Authors:  Ons Bouchami; Herminia de Lencastre; Maria Miragaia
Journal:  PLoS One       Date:  2016-06-01       Impact factor: 3.240

5.  A bacteriocin-based treatment option for Staphylococcus haemolyticus biofilms.

Authors:  Christian Kranjec; Sofie S Kristensen; Karolina T Bartkiewicz; Mikkel Brønner; Jorunn P Cavanagh; Aparna Srikantam; Geir Mathiesen; Dzung B Diep
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379

6.  High-Quality Genome Sequence of the Highly Resistant Bacterium Staphylococcus haemolyticus, Isolated from a Neonatal Bloodstream Infection.

Authors:  Farideh Hosseinkhani; Mohammad Emaneini; Willem van Leeuwen
Journal:  Genome Announc       Date:  2017-07-20

7.  Identifying gram-positive cocci in dermatoscopes and smartphone adapters using MALDI-TOF MS: a cross-sectional study.

Authors:  Maurício de Quadros; Roberto Carlos Freitas Bugs; Renata de Oliveira Soares; Adriana Medianeira Rossato; Lisiane da Luz Rocha; Pedro Alves d'Azevedo
Journal:  An Bras Dermatol       Date:  2020-03-21       Impact factor: 1.896

8.  Biofilm Formation by ica-Negative Ocular Isolates of Staphylococcus haemolyticus.

Authors:  Sasmita Panda; Durg Vijai Singh
Journal:  Front Microbiol       Date:  2018-11-14       Impact factor: 5.640

9.  Pathogenesis of Staphylococcus haemolyticus on primary human skin fibroblast cells.

Authors:  Hala O Eltwisy; Medhat Abdel-Fattah; Amani M Elsisi; Mahmoud M Omar; Ahmed Aly Abdelmoteleb; Mohamed A El-Mokhtar
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

10.  Therapeutic Effect of Darkling Beetle (Zophobas morio) Hemolymph on Skin Thermal Injury in Mice Infected by Staphylococcus haemolyticus.

Authors:  Shu-Xian Li; Ning Liu; Meng-Ze Du; Yao-Hong Zhu
Journal:  Vet Sci       Date:  2021-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.